FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

AbbVie’s popular arthritis drug Humira is a powerhouse, producing $14 billion in annual sales to make up 60 percent of the drugmaker’s revenue. However, generic versions of the drug are around the ...

Humira, AbbVie’s anti-inflammatory drug that has dozens of patents and $114 billion in U.S. sales, has a tight grasp on its market. That’s soon to change, The New York Times reported Jan. 28. Since ...

Please provide your email address to receive an email when new articles are posted on . Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just ...

A top California health plan is set to offer one of the world’s biggest-selling drugs for free in a bid to show the medicine can reach Americans affordably without going through the middlemen that ...

The PAS is supported by data from the REFLECTIONS B538-12 study, which assessed multiple switches between Abrilada and Humira, in addition to methotrexate, in adults with moderate to severe rheumatoid ...

UnitedHealth Group’s pharmacy benefit manager Optum Rx Tuesday said it will put three less expensive “biosimilar” versions of Abbvie’s pricey rheumatoid arthritis drug Humira “in the same position as ...

Please provide your email address to receive an email when new articles are posted on . On May 11, Icelandic-based drug developer Alvotech filed a lawsuit against AbbVie seeking to undo what it ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...